NASDAQ:BCLI - Brainstorm Cell Therapeutics Stock Price, Price Target & More Sign in or create an account to add this stock to your watchlist. Get Started $4.23 +0.07 (+1.68 %) (As of 07/15/2018 03:08 PM ET)Previous Close$4.23Today's Range$4.13 - $4.2552-Week Range$2.88 - $5.35Volume24,901 shsAverage Volume99,383 shsMarket Capitalization$85.66 millionP/E Ratio-16.27Dividend YieldN/ABeta2.07 Company ProfileFinancialsAnalyst RatingsEarnings HistoryInsider TradesHeadlinesOptions ChainSEC FilingsSocial MediaChart Share on FacebookShare on TwitterShare on LinkedInShare on RedditShare on StocktwitsPrint this articleShare by Email Brainstorm Cell Therapeutics Inc., a biotechnology company, engages in the development and commercialization of central nervous system (CNS) adult stem cell therapies designed to address the unmet medical needs of patients with debilitating neurodegenerative diseases. The company holds rights to develop and commercialize its NurOwn technology that utilizes a patient's own cells, which are engineered outside the body, to produce and secrete factors known to promote neuronal survival. It is developing NurOwn for various neurodegenerative diseases, including its lead indication, which is in Phase III clinical trial for the treatment of amyotrophic lateral sclerosis, as well as in preclinical trial for the treatment of multiple sclerosis, Parkinson's disease, Huntington's disease, and autism spectrum disorder. The company was formerly known as Golden Hand Resources Inc. and changed its name to Brainstorm Cell Therapeutics Inc. in November 2004 to reflect its new line of business in the development of novel cell therapies for neurodegenerative diseases. Brainstorm Cell Therapeutics Inc. was founded in 2000 and is headquartered in New York, New York. Receive BCLI News and Ratings via Email Sign-up to receive the latest news and ratings for BCLI and its competitors with MarketBeat's FREE daily newsletter. Industry, Sector and Symbol Stock Exchange NASDAQ Industry Biological products, except diagnostic Sub-IndustryN/A SectorMedical SymbolNASDAQ:BCLI CUSIPN/A Webwww.brainstorm-cell.com Phone201-488-0460 Debt Debt-to-Equity RatioN/A Current Ratio1.41 Quick Ratio1.41 Price-To-Earnings Trailing P/E Ratio-16.27 Forward P/E Ratio-7.42 P/E GrowthN/A Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / CashN/A Book Value$0.31 per share Price / Book13.65 Profitability EPS (Most Recent Fiscal Year)($0.26) Net Income$-4,950,000.00 Net MarginsN/A Return on Equity-98.51% Return on Assets-54.43% Miscellaneous Employees24 Outstanding Shares20,250,000Market Cap$85.66 Brainstorm Cell Therapeutics (NASDAQ:BCLI) Frequently Asked Questions What is Brainstorm Cell Therapeutics' stock symbol? Brainstorm Cell Therapeutics trades on the NASDAQ under the ticker symbol "BCLI." How were Brainstorm Cell Therapeutics' earnings last quarter? Brainstorm Cell Therapeutics Inc (NASDAQ:BCLI) released its quarterly earnings results on Monday, May, 14th. The biotechnology company reported ($0.12) EPS for the quarter, topping the Thomson Reuters' consensus estimate of ($0.14) by $0.02. View Brainstorm Cell Therapeutics' Earnings History. When is Brainstorm Cell Therapeutics' next earnings date? Brainstorm Cell Therapeutics is scheduled to release their next quarterly earnings announcement on Monday, August, 13th 2018. View Earnings Estimates for Brainstorm Cell Therapeutics. What price target have analysts set for BCLI? 2 brokers have issued 1 year price objectives for Brainstorm Cell Therapeutics' stock. Their predictions range from $9.00 to $11.00. On average, they expect Brainstorm Cell Therapeutics' stock price to reach $10.00 in the next year. This suggests a possible upside of 136.4% from the stock's current price. View Analyst Ratings for Brainstorm Cell Therapeutics. What is the consensus analysts' recommendation for Brainstorm Cell Therapeutics? 2 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Brainstorm Cell Therapeutics in the last year. There are currently 2 buy ratings for the stock, resulting in a consensus recommendation of "Buy." What are Wall Street analysts saying about Brainstorm Cell Therapeutics stock? Here are some recent quotes from research analysts about Brainstorm Cell Therapeutics stock: 1. HC Wainwright analysts commented, "We note that Right to Try" laws exist in 38 states, today: Alabama, Arizona, Arkansas, California, Colorado, Connecticut, Florida, Georgia, Idaho, Illinois, Indiana, Iowa, Kentucky, Louisiana, Maine, Maryland, Michigan, Minnesota, Mississippi, Missouri, Montana, Nevada, New Hampshire, North Carolina, North Dakota, Ohio, Oklahoma, Oregon, Pennsylvania, South Carolina, South Dakota, Tennessee, Texas, Utah, Virginia, West Virginia, Washington and Wyoming — but this federal bill would introduce legislation across state lines." (5/29/2018) 2. Maxim Group analysts commented, "Representatives passed a Right-to-Try" bill, to give terminally ill patients (i.e. ALS) access to experimental therapies that have completed Phase I studies (safety and/or early efficacy), are still in development, but do not yet have FDA approval. In addition, patients must not be eligible for clinical trials and have exhausted all other treatment options. The national legislation is likely to be passed into law in the coming weeks." (5/25/2018) Who are some of Brainstorm Cell Therapeutics' key competitors? Some companies that are related to Brainstorm Cell Therapeutics include Cellular Biomedicine Group (CBMG), Vericel (VCEL), Neon Therapeutics (NTGN), Adverum Biotechnologies (ADVM), MeiraGTx (MGTX), Jounce Therapeutics (JNCE), Nantkwest (NK), Allena Pharmaceuticals (ALNA), Agenus (AGEN), Idera Pharmaceuticals (IDRA), ADMA Biologics (ADMA), Fennec Pharmaceuticals (FENC), Krystal Biotech (KRYS), Compugen (CGEN) and Organovo (ONVO). Who are Brainstorm Cell Therapeutics' key executives? Brainstorm Cell Therapeutics' management team includes the folowing people: Mr. Chaim Lebovits, Pres & CEO (Age 47)Dr. Ralph Z. Kern, COO & Chief Medical Officer (Age 60)Mr. Uri Yablonka, Exec. VP, Chief Bus. Officer & Director (Age 41)Mr. Eyal Rubin, CFO & Treasurer (Age 42)Dr. Yael Gothelf Ph.D., VP of Scientific and Regulatory Affairs Has Brainstorm Cell Therapeutics been receiving favorable news coverage? News coverage about BCLI stock has been trending somewhat positive this week, Accern Sentiment Analysis reports. The research group identifies negative and positive media coverage by analyzing more than 20 million news and blog sources in real time. Accern ranks coverage of public companies on a scale of negative one to positive one, with scores nearest to one being the most favorable. Brainstorm Cell Therapeutics earned a news impact score of 0.13 on Accern's scale. They also gave media stories about the biotechnology company an impact score of 46.76 out of 100, indicating that recent media coverage is somewhat unlikely to have an impact on the company's share price in the near term. How do I buy shares of Brainstorm Cell Therapeutics? Shares of BCLI can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab. What is Brainstorm Cell Therapeutics' stock price today? One share of BCLI stock can currently be purchased for approximately $4.23. How big of a company is Brainstorm Cell Therapeutics? Brainstorm Cell Therapeutics has a market capitalization of $85.66 million. The biotechnology company earns $-4,950,000.00 in net income (profit) each year or ($0.26) on an earnings per share basis. Brainstorm Cell Therapeutics employs 24 workers across the globe. How can I contact Brainstorm Cell Therapeutics? Brainstorm Cell Therapeutics' mailing address is 1745 BROADWAY 17TH FLOOR, NEW YORK NY, 10019. The biotechnology company can be reached via phone at 201-488-0460 or via email at [email protected] MarketBeat Community Rating for Brainstorm Cell Therapeutics (NASDAQ BCLI)Community Ranking: 3.0 out of 5 ( )Outperform Votes: 151 (Vote Outperform)Underperform Votes: 98 (Vote Underperform)Total Votes: 249MarketBeat's community ratings are surveys of what our community members think about Brainstorm Cell Therapeutics and other stocks. Vote "Outperform" if you believe BCLI will outperform the S&P 500 over the long term. Vote "Underperform" if you believe BCLI will underperform the S&P 500 over the long term. You may vote once every thirty days. This page was last updated on 7/15/2018 by MarketBeat.com StaffFeatured Article: Should you buy a closed-end mutual fund?